44 participants
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2006-11-08
- Start Date:
- 2004-05-31
Conditions
- Ovarian Cancer
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
Interventions
- BIOLOGICAL
No Results Yet